Trials / Sponsors / Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc.
Industry · 6 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Completed | Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Re Cancer | Phase 1 / Phase 2 | 2021-01-12 |
| Terminated | Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects Wit NSCLC | Phase 2 | 2020-10-19 |
| Terminated | Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cyto Cancer | Phase 1 / Phase 2 | 2020-03-10 |
| Completed | Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Canc Cancer | Phase 2 | 2019-06-06 |
| Completed | Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies Cancer | Phase 1 | 2018-12-06 |
| Completed | JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory So Cancer | Phase 1 / Phase 2 | 2016-08-01 |